6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS

Abstract

The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.

1 .- 15 . (canceled) 
     
     
         16 . A method of treating a central nervous system disorder or condition comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula 
       
         
           
           
               
               
           
         
       
       or a stereoisomeric form, a N-oxide, or a pharmaceutically acceptable salt thereof. 
     
     
         17 . A method of treating a central nervous system disorder or condition comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula 
       
         
           
           
               
               
           
         
       
       or a stereoisomeric form, a N-oxide, or a pharmaceutically acceptable salt thereof. 
     
     
         18 . The method of  claim 16  wherein the central nervous system disorder or condition is a mood disorder. 
     
     
         19 . The method of  claim 18  wherein the mood disorder is selected from major depressive disorder, depression and treatment resistant depression. 
     
     
         20 . The method of  claim 16  wherein the central nervous system disorder or condition is selected from the group consisting of anxiety, depression, dementia of the Alzheimer's type and schizophrenia. 
     
     
         21 . The method of  claim 17  wherein the central nervous system disorder or condition is a mood disorder. 
     
     
         22 . The method of  claim 21  wherein the mood disorder is selected from major depressive disorder, depression and treatment resistant depression. 
     
     
         23 . The method of  claim 17  wherein the central nervous system disorder or condition is selected from the group consisting of anxiety, depression, dementia of the Alzheimer's type and schizophrenia.